1 Efficacy of a novel anti-inflammatory drug-eluting balloon coated with genistein before stent implantation in porcine coronary arteries I. Sheiban, C.

Slides:

Advertisements

Similar presentations

Impact of Diabetes Mellitus on Early and Long-term Results of Percutaneous Drug- eluting Stent Implantation for Unprotected Left Main Coronary Disease.

Advertisements

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

PCI Unmet Clinical Needs

1 SUPERIORITY OF A HIGH CLOPIDOGREL LOADING DOSE REGIMEN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: EVIDENCE FROM A META-ANALYSIS G. BIONDI-ZOCCAI1,

Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)

Can we prevent stent restenosis after coronary stent implantation

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.

New generation devices for the femoro-popliteal district Giuseppe Biondi Zoccai University of Modena and Reggio Emilia

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.

METHODS Articles used included randomized controlled clinical trials of adults ranging from 50 to 75 years of age who had undergone either angioplasty.

M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.

Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.

Biondi-Zoccai: Peripheral interventions – metcardio.org Basic principles of peripheral interventions Giuseppe Biondi Zoccai University.

The Science Behind Taxus Advanced Angioplasty 2004 Christian Vander Velde, Boston Scientific Europe, Marketing.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.

1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.

Title1 Brain Natriuretic Peptide Levels Have A Significant Prognostic Role In Patients With Suspected Or Confirmed Acute Pulmonary Embolism: Evidence From.

1 Percutaneous Below-The-Knee Stent Implantation Among 468 Patients With Critical Limb Ischemia: Pooled Analysis And Comparison Of Drug-Eluting Versus.

PLATINUM A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Objective To evaluate.

1 ASSESSMENT OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION BY TISSUE DOPPLER IMAGING SHOWS EVIDENCE OF SUBCLINICAL CARDIOMYOPATHY EARLY AFTER ATHRACYCLINE THERAPY.

Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

1 HIGH CLOPIDOGREL LOADING DOSE IS SUPERIOR TO A STANDARD 300 MG REGIMEN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: EVIDENCE FROM A META-ANALYSIS.

Gender-related differences in carotid plaque features: focus on instability and inflammation Giuseppe Biondi Zoccai, MD University of Modena and Reggio.

WHY TITAN WORKS AGAINST RESTENOSIS?. INTRODUCTION THE CELL MODEL THE HUMAN THE ANIMAL MODEL CONCLUSION WHY TITAN WORKS AGAINST RESTENOSIS ?

Need Statement and Need Criteria. Need Statement To prevent the reoccurrence of stenosis in coronary arteries. More specifically, to create a solution.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.

1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Vascular Inflammation and Repair: Implications for.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.

Real-world clinical experience with an everolimus eluting platinum chromium stent with an abluminal biodegradable polymer – a report from the Swedish Coronary.

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

Total Occlusion Study of Canada (TOSCA-2) Trial

The MASS-DAC Study.

insights from a meta-analysis of

From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):

Date of download: 10/27/2017 Copyright © ASME. All rights reserved.

Bioabsorbable DES and Biodegradable Polymers – FDA View

DES Bioabsorbable and DCB Technologies

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

The OrbusNeich EPC Capture Biodegradable Polymer Sirolimus-eluting Stent Program Michael JB Kutryk, MD, PhD St Michael’s Hospital, Toronto.

Giuseppe Biondi Zoccai

Giuseppe Biondi Zoccai

Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,

Background There is ongoing debate to identify the most effective drug-eluting stent between the two currently most used devices (ie, sirolimus- [SES]

Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.

Giuseppe Biondi Zoccai, MD

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.

P. Omedé,1 A. Abbate,4 G. P. Trevi,1 and I. Sheiban1

PREDICTORS OF ADVERSE EVENTS IN PATIENTS WITH UNPROTECTED LEFT MAIN DISEASE TREATED WITH DRUG-ELUTING STENTS: EVIDENCE FROM A COLLABORATIVE META-REGRESSION.

BENEFITS OF CLOPIDOGREL IN PATIENTS UNDERGOING CORONARY STENTING SIGNIFICANTLY DEPEND ON LOADING DOSE: EVIDENCE FROM A SYSTEMATIC REVIEW AND META-REGRESSION.

Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.

ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.

Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.

Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.

Primary safety endpoint

The American College of Cardiology Presented by Dr. A. Abazid

Presentation transcript:

1 Efficacy of a novel anti-inflammatory drug-eluting balloon coated with genistein before stent implantation in porcine coronary arteries I. Sheiban, C. Moretti, M. Anselmino, G. Biondi-Zoccai, P. Omedé, F. Sciuto, M. Galloni, and G. P. Trevi University of Turin, Turin, Italy

2 BACKGROUND Drug-eluting stents using cytostatic drugs significantly reduce restenosis after percutaneous coronary intervention, but may be associated with persistent local inflammation. Coating coronary devices with potent anti- inflammatory agents such as the flavonoid genistein may provide significant benefits, without unduly promoting inflammation.

3 BACKGROUND A novel genistein-eluting balloon has been developed by Sahajanand (Gujarat, India), with promising in vitro data, but no in vivo/preclinical data. We thus aimed to test in a porcine model the safety and efficacy of a novel genistein-eluting balloon before coronary stent implantation.

4 METHODS Female piglets underwent PCI in 25 coronary segments in a randomized fashion with either a genistein-eluting balloon or a standard balloon, followed by bare-metal stent implantation at 1.1:1.0 balloon to artery ratio. Pigs were then sacrificed at different time points to appraise safety (i.e. endothelialization) and efficacy (i.e. anti-inflammatory and anti- proliferative effects): 1, 4, and 6 to 8 weeks after PCI.

5 STUDY PROFILE DEB=drug-eluting balloon SB=standard balloon

6 RESULTS Overall analysis was conducted on 14 piglets treated with 25 standard bare-metal stents were implanted, of which 13 with conventional angioplasty balloon and 12 with the genistein- eluted angioplasty balloon. The genistein-eluting balloon proved safe, as no untoward effects were found in any of the animals, including those sacrificed as early as 1 week post-PCI, with healing and endothelialization appearing almost universal in all stent struts within four weeks.

7 RESULTS The drug-eluting balloon also showed significant biologic efficacy, as at 4 weeks animals treated with this device had a significant reduction in peri-stent inflammatory cells (39±32 vs 96±29, p= 0.019). This statistically significant anti-inflammatory effect translated into non-significant trends towards reduced neointimal hyperplasia (measured as neointimal thickness) at eight weeks (0.13±0.11 mm vs. 0.15±0.09 mm, p>0.05).

8 RESULTS 46N = Drug-eluting balloon yesno % stenosis N = Drug-eluting balloon yesno Neointimal thickness (mm),3,2,1 0,0 p=0,788 p=0,319

9 RESULTS 46N = Drug-eluting balloon yesno Injury score 1,2 1,0,8,6,4,2 0,0 46N = Drug-eluting balloon yesno MNCs x mm p=0,630 p=0,019

10 HISTOLOGY OF GENISTEIN-ELUTING BALLOON (A) VERSUS CONVENTIONAL ANGIOPLASTY BALLOON (B) FOLLOWED BY CORONARY STENTING AT FOUR WEEKS

11 4-WEEK PERI-STENT CELLULARITY AFTER CONVENTIONAL BALLOON (TOTAL CELLULARITY IN A, MNC IN B) VS GENISTEIN-ELUTING BALLOON (TOTAL CELLULARITY IN C, MNC IN D) WITH ARROWS INDICATING MNC.

12 CONCLUSIONS This study provides the first in vivo demonstration of the anti-inflammatory effects of a novel genistein-eluting balloon in percutaneous coronary stenting. Further research is warranted to appraise whether the combination of a genistein- eluting balloon with standard drug-eluting stent can provide both anti-restenotic and anti-inflammatory effects.

For further slides on these topics please feel free to visit the metcardio.org website: